Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose Escalation Study of Ibrutinib With Lenalidomide for Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT01886859 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT01886859
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01886859 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose Escalation Study of Ibrutinib With Lenalidomide for Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Completed
Start date
April 26, 2013
Completion date
September 21, 2022
Enrollment
27 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent b-cell prolymphocytic leukemia, recurrent chronic lymphocytic leukemia, recurrent small lymphocytic lymphoma, refractory b-cell prolymphocytic leukemia, refractory chronic lymphocytic leukemia, refractory small lymphocytic lymphoma